Despite the clear advantages of screening for early-stage, more treatable lung cancer, a surprisingly low percentage of eligible Americans undergo recommended screening. While current guidelines for lung cancer screening are largely consistent, the nuances in interpreting and applying these criteria to the patient in front of you can be perplexing, leading to lower screening rates. Utilizing clinical cases and related questions, faculty educator Carla Lamb, MD, FACP, FCCP (Lahey Hospital & Medical Center), addresses these key points, offering guidance on how to identify high-risk patients suitable for screening. Additionally, it will provide strategies to facilitate shared decision-making with patients, focusing on a comprehensive discussion of the benefits and risks associated with screening.
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
At the conclusion of the activity, learners should be better able to:
